The upgrade from Neutral to Buy indicates a positive outlook for Mirati Therapeutics, which could lead to an increase in its stock price. However, the lowering of the price target from $51 to $48 suggests a potential decrease in the stock's value. The net effect is likely to be positive, but less so than if the price target had been raised.